Alkermes plc (ALKS) - Stock Analysis
Last updated: Mar 28, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Sleep/psychiatry platform with newly de-risked pipeline: FDA Breakthrough Therapy designation and the launch of the Brilliance Phase 3 program for alixorexton plus the Avadel (LUMRYZ) acquisition, backed by >$1.1B cash and strong FCF, have driven ~20% 21-day price gains and position the stock for further short-term upside if momentum above ~$35 holds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Net cash position ⢠High margins & FCF ⢠Accumulated deficit Alkermes is a cash-rich, low-leverage, cash-generative biopharma with strong margins and FCF but notable operating-costs, sizable working capital and a lingering accumulated deficit that warrant investor scrutiny.
Price Behavior
Key Price Behavior Insights: ⢠Above SMA ⢠Near resistance ⢠Rapid rebound Support Level: $27.20â$27.80 Resistance Level: $30.25 Price has recovered off midâMarch lows and sits above the lastâmonth SMA (~$28.50), trading near resistance at $30.25âclear break above $30.25 would signal bullish continuation, while failure risks a pullback toward $27.2â$27.8 support.
Sentiment & News
Key News Insights: ⢠Investor outreach ⢠New APN program ⢠Stake reduction Alkermes launched investor outreach and an APN research awards program while facing a large stake reduction, a Zacks Strong Sell placement, and near-term share weakness.
AI Summary
Alkermes' pivot to pairing stable legacy cash flows with highârisk orexin R&D is fundable by a strong balance sheet, but the investment is only attractive if Avadel/LUMRYZ demonstrates a clear revenue/margin ramp and alixorexton is deârisked in Phase III â wait for LUMRYZ uptake and stabilized cashâflow/guidance before increasing exposure.
Description
Alkermes plc is a Dublin-based biopharmaceutical company that develops and commercializes medicines for psychiatric and neurological disorders and has operations in the United States, Ireland and other markets. Its commercial portfolio includes long-acting injectable and oral treatments for schizophrenia, bipolar disorder and substance-use disorders, as well as a product for relapsing forms of multiple sclerosis. The company maintains a pipeline that includes an oral atypical antipsychotic candidate and an engineered immunotherapy for oncology, and it holds collaboration agreements with Janssen entities.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 2 | Apr 9 | ALKS | Alkermes plc | Sleep/psychiatry platform with newly de-risked pipeline: FDA Breakthrough Therapy designation and the launch of the Brilliance Phase 3 program for alixorexton plus the Avadel (LUMRYZ) acquisition, backed by >$1.1B cash and strong FCF, have driven ~20% 21-day price gains and position the stock for further short-term upside if momentum above ~$35 holds. | Active | +0.0% |